Share on StockTwits
 

Shares of Valeant Pharmaceuticals (NYSE:VRX) reached a new 52-week high during trading on Tuesday , AnalystRatingsNetwork reports. The company traded as high as $142.20 and last traded at $141.93, with a volume of 1,112,889 shares changing hands. The stock had previously closed at $138.13.

VRX has been the subject of a number of recent research reports. Analysts at UBS AG raised their price target on shares of Valeant Pharmaceuticals from $125.00 to $141.00 in a research note on Wednesday, January 8th. They now have a “buy” rating on the stock. Separately, analysts at TD Securities downgraded shares of Valeant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Finally, analysts at Ladenburg Thalmann raised their price target on shares of Valeant Pharmaceuticals from $123.00 to $155.00 in a research note on Wednesday, January 8th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals has an average rating of “Buy” and a consensus target price of $127.96.

The stock’s 50-day moving average is $128.8 and its 200-day moving average is $110.7. The company’s market cap is $47.182 billion.

In other Valeant Pharmaceuticals news, Director Norma Ann Provencio sold 5,000 shares of the stock on the open market in a transaction dated Monday, February 3rd. The stock was sold at an average price of $136.23, for a total transaction of $681,150.00. Following the transaction, the director now directly owns 147,206 shares in the company, valued at approximately $20,053,873. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.